PSC
OREX

Piper Sandler & Co’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Piper Sandler & Co’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-981
Closed -$17K – 33
2015
Q4 		$17K Buy
+981
New +$23.4K 0.04% 24
2015
Q2 		– Sell
-7,000
Closed -$548K – 156
2015
Q1 		$548K Buy
+7,000
New +$434K 0.23% 42

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piper Sandler & Co's OREX Position: Q1 2016 in Review

Piper Sandler & Co sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 981 shares — an estimated $17K sold.

Piper Sandler & Co first reported a position in OREX in Q1 2015 and held it in 2 quarters. The position peaked at $548K in Q1 2015. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • Piper Sandler & Co reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Piper Sandler & Co sold 981 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $17K.
  • Piper Sandler & Co first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
  • Piper Sandler & Co's Orexigen Therapeutics, Inc. position peaked at $548K in Q1 2015.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Piper Sandler & Co's 13F filing for Q1 2016, filed 16 May 2016.